The Times Australia
Google AI
PR Newswire

.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

ZÜRICH, Nov. 9, 2020 /PRNewswire/ -- Concept Medical Inc.,[1] focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the SirPAD (Sirolimus in Peripheral Artery Disease) trial.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

SirPAD[2] is the first All-Comer randomized controlled clinical trial (RCT) investigating major adverse limb events in PAD patients with lesions below the inguinal ligament.

SirPAD[3] is investigator-initiated, single-center, randomized, non-inferiority, open-label clinical trial investigating whether the use of MagicTouch PTA[4] sirolimus-coated balloon catheters in patients with peripheral artery disease of the femoro-popliteal or below-the-knee segment is not inferior to that of uncoated balloon catheters for major clinical outcomes (unplanned major amputation, target limb re-vascularization). Total of 1200 patients are to be randomized 1:1 (600 patients per treatment group).

The primary objective is to evaluate whether the use of sirolimus-coated balloon catheters (MagicTouch PTA[5]) is non-inferior to uncoated balloon catheters in infra-inguinal angioplasty to prevent one-year major adverse limb events (MALE), including unplanned major amputation of the target limb and target lesion re-vascularization for critical limb ischemia, in a representative population of patients with PAD (`all-comers`). If the criterion for non-inferiority is confirmed, the study will test whether sirolimus-coated catheters (MagicTouch PTA[6]) are superior to uncoated catheters for important secondary outcomes and for the primary outcome itself according to pre-specified criteria for hierarchical analysis.

The index patient was successfully enrolled on 3rdNovember 2020 in University Hospital Zurich.

The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

Prof. Dr. med Nils Kucher was excited to initiate the study and said, "Over the past decade, a few RCTs have compared the efficacy and safety of drug-coated (mainly paclitaxel-coated) devices vs. that of uncoated ones, and demonstrated a significant reduction in restenosis rates, late lumen loss, and incidence of target lesion re-vascularization. However, the size of these trials was often too small to draw firm conclusions concerning major clinical outcomes. Moreover, substantial heterogeneity of the study populations and too restrictive eligibility criteria limited their external validity, leading to a difficult interpretation of the results of meta-analyses. Indeed, these trials adopted surrogate (and rather subjective) outcomes as the primary outcome, such as vessel patency and target limb re-vascularization, which may be difficult to objectively judge in the setting of an open-label trial, rather than ´hard´ objective clinical endpoints, such as major amputation or urgent revascularization due to critical limb ischemia. The aim of the SirPAD trial is to compare the efficacy, as defined by a composite of clinically relevant non-subjective 'hard' outcomes (major amputation and target lesion re-vascularization for critical limb ischemia), of sirolimus-coated vs. uncoated balloon angioplasty for peripheral artery disease in patients."

www.conceptmedical.com[7]

Photo:https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600[8]

Logo: https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600[9]

Source: Concept Medical Inc.

References

  1. ^ Concept Medical Inc., (www.conceptmedical.com)
  2. ^ SirPAD (www.conceptmedical.com)
  3. ^ SirPAD (www.conceptmedical.com)
  4. ^ MagicTouch PTA (www.conceptmedical.com)
  5. ^ MagicTouch PTA (www.conceptmedical.com)
  6. ^ MagicTouch PTA (www.conceptmedical.com)
  7. ^ www.conceptmedical.com (www.conceptmedical.com)
  8. ^ https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600 (mma.prnasia.com)
  9. ^ https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600 (mma.prnasia.com)

Read more https://www.prnasia.com/story/archive/3184609_AE84609_0

Business Times

Australia has set new expectations for AI data centres – they sho…

Yesterday, the Australian federal government released new expectations[1] for data centres and artificial intelligence ...

AI Is Already Here. The Question Is Whether Your Business Is Buil…

We sat down with Nirlep Adhikari — CTO at LoanOptions.ai and Founder of Mount Mindforce — to cut through the noise and ta...

Is Hiring a Web Developer Still Worth It?

It’s a fair question to ask in 2026. With AI tools promising to build you a website in minutes and drag-and-drop platform...

The Times Features

Grants open for port communities across the Hunter and Northern Rivers regions

Local organisations doing important work across the Hunter and Northern Rivers regions are being...

AI Is Already Here. The Question Is Whether Your Business Is Built for It

We sat down with Nirlep Adhikari — CTO at LoanOptions.ai and Founder of Mount Mindforce — to cut...

Cleared to Land — and Cleared to Die: How a Runway Failure Killed Two Pilots in Seconds

A modern passenger jet, operating under full clearance, descending onto a controlled runway at o...

Leader of The Nationals Matt Canavan - press conference

CANBERRA PARLIAMENT HOUSE PRESS CONFERENCE WITH SHADOW WATER MINISTER MICHAEL McCORMACK; MURRAY-DA...

The Power Of An Uncomfortable Love

How challenging relationships can help us grow. Never have we lived in a time where relationshi...

US country favourite Larry Fleet joins 2026 Gympie Music Muster

Tennessee singer-songwriter Larry Fleet will bring his band to the Gympie Music Muster on Friday...

56 OF YOUR FAVORITE DISNEY STARS SHINE BRIGHT IN DISNEY ON ICE PRESENTS MAGIC IN THE STARS!

The most Disney characters in one show and the on-ice debut of Raya from Raya and the Last Dragon...

How much do you really need to retire? It’s probably a lot less than $1 million

Every few months, someone in the superannuation industry declares that Australians now “need” ar...

South Australian Nationals to open up local oil from Great Australian Bight

Amid out-of-control inflation and impacts from the Middle East conflict, The South Australian Na...